ObjectiveTo study the influence of estrogen on zoledronic acid in preventing bone metastasis of breast cancer. MethodsTwo hundred and sixteen breast cancer patients who accepted modified radical mastectomy, chemotherapy, and the prophylaxis of zoledronate acid from January 2006 to December 2009 in this hospital were collected, including luminal A 55 cases, luminal B 63 cases, HER-2 positive 50 cases, triple negative 48 cases. Then these patients were categorized into low estrogen group(n=39) and normal estrogen group(n=177) according to the estrogen level. The patients in the low estrogen group accepted drug induced menopause, in the normal estrogen group didn't accept drug induced menopause. All the patients accepted the therapy of zoledronate acid, then with clinical follow-up for 3-5 years until progressive disease(include neoplasm recurrence, bone metastasis, and other neoplasm metastasis etc.). ResultsThe rate of bone metastasis in the low estrogen group was significantly lower than that in the normal estrogen group (χ2=21.91, P < 0.05). For the patients with luminal A, luminal B, HER-2 positive, and triple negative, the rates of bone metastases in the low estrogen group were significantly lower than those in the normal estrogen group[luminal A:5.13%(2/39) versus 12.43%(22/177), χ2=4.54, P < 0.05;luminal B:7.69%(3/39) versus 13.56%(24/177), χ2=6.04, P < 0.05;HER-2 postive:2.56%(1/39) versus 15.25%(27/177), χ2=3.95, P < 0.05;triple negative:2.56% (1/39) versus 18.08%(32/177), P < 0.05]. The rate of bone metastasis among the different subtype of breast cancer in the low estrogen group was not significant difference(χ2=0.55, P > 0.05). ConclusionsFrom the limited preliminary data, the premenopausal women patients with breast cancer who accepted drug induced menopause afer application of zoledronate acid for preverttion of bone metastasis has a obviously efficacy, and the efficacy has no difference among four molecular subtypes of breast cancer.
ObjectiveTo study the preventive effect of zoledronic acid on the bone metastases of breast cancer. MethodsFour hundred and eighteen female patients with infiltrating ductal carcinoma who were underwent surgery in The First Affiliated Hospital of Xinjiang Medical University from Jan. 2006 to Dec. 2009 were collected and divided into 2 group, patients of prevention group accepted the preventive remedy of zoledronic acid(n=216), but patients of control group didn't accept(n=202). Comparison of incidence of bone metastases and recurrence was performed. ResultsThere were 37(17.13%) patients suffered bone metastases in prevention group and 73(36.14%) patients in control group, so the incidence of bone metastases was higher in control group(χ2=19.45, P<0.05). But there were no significant difference on incidence of pulmonary metastasis, liver metastases, other parts of metastases, multiple organ metastases, and recurrence(P>0.05). ConclusionZoledronic acid could significantly reduce the incidence of bone metastases for patients with breast cancer, who underwent chemotherapy of conventional dose after operation, and it can effectively improve the prognosis of patients with breast cancer.
Objective To summary the advance of circulating tumor cells in breast cancer. Methods Through reviewing the related studies, a series of clinical studies on advance of circulating tumor cells in breast cancer were reviewed. Results For early breast cancer patients, the detection of circulating tumor cells could find patients at high risk of recurrence and metastasis. For metastatic breast cancer patients, it could assess the efficacy of adjuvant chemotherapy and predict the prognosis. To explore the molecular characteristics of circulating tumor cells could help to understand tumor transfer mechanism and seek new therapeutic targets. Conclusion Circulating tumor cells play an important role in the treatment of breast cancer, but many multi-center prospective studies are needed to ensure whether circulating tumor cells can be used in clinical practice.
ObjectiveTo investigate the correlation between abnormal thyroid function and benign or malignant breast tumors. MethodsThe contents of free iodine three original acid (FT3), three iodine original acid (T3), thyroxine (T4), free thyroxine (FT4), thyroid-stimulating hormone (TSH), anti-thyroglobulin antibodies (Anti-TG), and antithyroid peroxidase antibody (Anti-TPO) were detected by chemiluminescence method in 563 patients with benign breast neoplasms, 87 patients with breast cancer, and 123 health examination population. ResultsT3 and T4 levels in patients with breast cancer were lower than those of normal control group and benign tumor group (P < 0.05). However, there were no significant difference in the levels of FT3, FT4, and TSH between the 3 groups (P > 0.05). The positive rates of Anti-TPO and Anti-TG were higher than those of benign group and normal group (P < 0.001). T3 and T4 levels in patients with breast cancer were not related to the expression of ER and PR, in Her-2 negative expression and lymph node metastasis were relatively low (P < 0.05). ConclusionThe decrease of contents of T3 and T4, and the positive expressions of Anti-TPO and Anti-TG may provide a basis for predicting the incidence of breast cancer.
ObjectiveTo discuss related clinical research progress of bone metastasis of breast cancer. MethodThe literatures about bone metastases of breast cancer were researched and reviewed. ResultsAlthough there were so many related researches at home and abroad for bone metastasis of breast cancer,but the specific mechanism was still not fully elucidated.At present,the diagnostic method of bone metastasis of breast cancer included X-ray examination,bone scanning,computer tomography,magnetic resonance imaging,positron tomography,positron emission computed tomography,pathology biopsy,and detection of serum markers.In clinical treatment,the treatment consisted of systemic therapy and local therapy,but there was no uniform standard. ConclusionFor high incidence and serious influence on quality of life,bone metastasis of breast cancer needs to be studied further.
ObjectiveTo summarize the research progress of the cause, treatment, and other aspects in male breast cancer (MBC). MethodsThrough reading the related literatures, relevant literatures of MBC were reviewed. ResultsFamily history, BRCA1/2 mutation, the imbalance of level of estrogen and androgen, and other factors were risk factors of the MBC. Sentinel lymph node biopsy (SLNB) was feasible in the MBC. Radiotherapy could control local recurrence of MBC, and chemotherapy may be beneficial for long-term survival rate of MBC. The endocrine therapy principle for MBC was not exact as female breast cancer (FBC). ConclusionsMBC has many risk factors. Radiotherapy, chemotherapy, and endocrine therapy are benefit to MBC patients, but it still needs to be confirmed by many high-quality clinical researches of large sample.